AngioDynamics gets carte blanche to market spider vein therapy in US:
This article was originally published in Clinica
AngioDynamics, the developer of minimally-invasive devices for treating peripheral vascular conditions, is to gain at least $3m in additional sales of its sclerotherapy product Sotradecol, after amending its distribution agreement with the product's Quebec, Canada-based developer Bioniche Pharma. Under the terms of the new contract, Queensbury, New York-based AngioDynamic can now sell Sotradecol - said to be the only sodium tetradecyl sulfate injection approved by the FDA for treating spider veins - in all markets including doctors of all specialties, hospital pharmacies, group purchasing organisations and wholesalers. Previously, the company was limited to selling the compound to interventional radiologists, vascular and general surgeons and doctors specialising in certain areas.